Molecular Pathways in Metastatic Renal Cell Carcinoma: The Evolving Role of Mammalian Target of Rapamycin Inhibitors

European Urology, Supplements

Volumn 8, Issue 10, 2009, Pages 793-798

  Ravaud, Alain ^a,b   Wallerand, Hervé ^c  

^a HÔPITAL SAINT ANDRÉ   (France)

^b Centre of Clinical Investigation Clinical Epidemiology   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

Everolimus; Hypoxia inducible factors; Metastatic renal cell carcinoma; Molecular pathways; mTOR; Temsirolimus; von Hippel Lindau

Indexed keywords

BEVACIZUMAB; EVEROLIMUS; HYPOXIA INDUCIBLE FACTOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PLACEBO; RECOMBINANT ALPHA INTERFERON; RECOMBINANT INTERFERON; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN INHIBITOR; VATALANIB; VON HIPPEL LINDAU PROTEIN;

ANEMIA; ANGIOGENESIS; ASTHENIA; CANCER CHEMOTHERAPY; CELL GROWTH; CELL PROLIFERATION; CLINICAL TRIAL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TARGETING; DRUG WITHDRAWAL; DYSPNEA; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; INFECTION; KIDNEY CARCINOMA; KIDNEY METASTASIS; MONOTHERAPY; NAUSEA; PATHOGENESIS; PERIPHERAL EDEMA; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RASH; REVIEW; STOMATITIS; THROMBOCYTOPENIA;

EID: 70349335351     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2009.08.001     Document Type: Review

References (40)

1. Gupta K., Miller J.D., Li J.Z., Russell M.W., and Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 34 (2008) 193-205
2. Kaelin Jr. W.G. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res 10 (2004) 6290S-6295S
3. Latif F., Tory K., Gnarra J., et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260 (1993) 1317-1320
4. Herman J.G., Latif F., Weng Y., et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A 91 (1994) 9700-9704
5. van Houwelingen K.P., van Dijk B.A., Hulsbergen-van de Kaa C.A., et al. Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from the Netherlands cohort study. BMC Cancer 5 (2005) 57
6. Wiesener M.S., Munchenhagen P.M., Berger I., et al. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Cancer Res 61 (2001) 5215-5222
7. Iliopoulos O., Levy A.P., Jiang C., Kaelin Jr. W.G., and Goldberg M.A. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A 93 (1996) 10595-10599
8. Patel P.H., Chadalavada R.S., Chaganti R.S., and Motzer R.J. Targeting von Hippel-Lindau pathway in renal cell carcinoma. Clin Cancer Res 12 (2006) 7215-7220
9. Kolch W., Kotwaliwale A., Vass K., and Janosch P. The role of Raf kinases in malignant transformation. Expert Rev Mol Med 4 (2002) 1-18
10. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 (2007) 125-134
11. Bukowski R.M., Eisen T., Szczylik C., et al. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis. J Clin Oncol 25 June 20 Suppl (2007) abstract 5023
12. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
13. Figlin R.A., Hutson T.E., Tomczak P., et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). J Clin Oncol 26 May 20 Suppl (2008) abstract 5024
14. Ljungberg B, Hanbury DC, Kuczyk MA, et al. Guidelines on renal cell carcinoma. European Association of Urology Web site. http://www.uroweb.org/fileadmin/tx_eauguidelines/2009/Full/RCC.pdf. Accessed June 2009.
15. NCCN clinical practice guidelines in oncology: kidney cancer. National Comprehensive Cancer Network Web site. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed June 2009.
16. Gollob J.A., Rathmell W.K., Richmond T.M., et al. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol 25 (2007) 3288-3295
17. Ryan C.W., Goldman B.H., Lara Jr. P.N., et al. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol 25 (2007) 3296-3301
18. ASSURE: adjuvant sorafenib or sunitinib for unfavorable renal carcinoma [identifier: NCT00326898]. ClinicalTrials.gov Web site. http://clinicaltrials.gov/ct2/show/NCT00326898?term=nct00326898&rank=1. Updated August 28, 2009. Accessed September 2009.
19. Sunitinib treatment of renal adjuvant cancer (S-TRAC): a randomized double blind phase 3 study of adjuvant sunitinib vs. placebo in subjects at high risk of recurrent RCC [identifier: NCT00375674]. ClinicalTrials.gov Web site. http://clinicaltrials.gov/ct2/show/NCT00375674. Updated August 15, 2009. Accessed September 2009.
20. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434
21. Escudier B., Pluzanska A., Koralewski P., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370 (2007) 2103-2111
22. Rini B.I., Halabi S., Rosenberg J.E., et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26 (2008) 5422-5428
23. Sosman J.A., Flaherty K.T., Atkins M.B., et al. Updated results of phase I trial of sorafenib (S) and bevacizumab (B) in patients with metastatic renal cell cancer (mRCC). J Clin Oncol 26 May 20 Suppl (2008) abstract 5011
24. Feldman D.R., Ginsberg M.S., Baum M., et al. Phase I trial of bevacizumab plus sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 26 May 20 Suppl (2008) abstract 5100
25. Hanna S.C., Heathcote S.A., and Kim W.Y. mTOR pathway in renal cell carcinoma. Expert Rev Anticancer Ther 8 (2008) 283-292
26. Radulovic S., and Bjelogrlic S.K. Sunitinib, sorafenib and mTOR inhibitors in renal cancer. J BUON 12 (2007) S151-S162
27. Atkins M.B., Hidalgo M., Stadler W.M., et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22 (2004) 909-918
28. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356 (2007) 2271-2281
29. Lane H.A., Wood J.M., McSheehy P.M., et al. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res 15 (2009) 1612-1622
30. Jac J., Giessinger S., Khan M., Willis J., Chiang S., and Amato R. A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC). J Clin Oncol 25 June 20 Suppl (2007) abstract 5107
31. Amato R.J., Jac J., Giessinger S., Saxena S., and Willis J.P. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer 115 (2009) 2438-2446
32. Jac J., Amato R.J., Giessinger S., Saxena S., and Willis J.P. A phase II study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic renal cell carcinoma which has progressed on tyrosine kinase inhibition therapy. J Clin Oncol 26 May 20 Suppl (2008) abstract 5113
33. Motzer R.J., Escudier B., Oudard S., et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372 (2008) 449-456
34. Escudier B., Ravaud A., Oudard S., et al. Phase-3 randomized trial of everolimus (RAD001) vs placebo in metastatic renal cell carcinoma [abstract 72]. Ann Oncol 19 (2008) viii45
35. Motzer R, Kay A, Figlin R, et al. Updated data from a phase III randomized trial of everolimus (RAD001) versus PBO in metastatic renal cell carcinoma (mRCC). ASCO 2009 Genitourinary Cancers Symposium [abstract 278]. American Society of Clinical Oncology Web site. http://www.asco.org/ASCOv2/MultiMedia/Virtual+Meeting?&vmview=vm_session_presentations_view&confID=64&sessionID=11. Accessed June 2009.
36. Hudes G.R. Targeting mTOR in renal cell carcinoma. Cancer 115 (2009) 2313-2320
37. Speca J.C., Mears A.L., Creel P.A., et al. Phase I study of PTK787/ZK222584 (PTK/ZK) and RAD001 for patients with advanced solid tumors and dose expansion in renal cell carcinoma patients. J Clin Oncol 25 June 20 Suppl (2007) abstract 5039
38. Rosenberg J.E., Weinberg V.K., Claros C., et al. Phase I study of sorafenib and RAD001 for metastatic clear cell renal cell carcinoma. J Clin Oncol 26 May 20 Suppl (2008) abstract 5109
39. Whorf R.C., Hainsworth J.D., Spigel D.R., et al. Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC). J Clin Oncol 26 May 20 Suppl (2008) abstract 5010
40. Bracarda S., and Ravaud A. Current and future treatment options for metastatic renal cell carcinoma. Eur Urol Suppl 8 (2009) 799-808